A

Arvin C. Dar

Memorial Sloan Kettering Cancer Center

ORCID: 0000-0003-0318-4848

Publishes on Melanoma and MAPK Pathways, Lung Cancer Treatments and Mutations, PARP inhibition in cancer therapy. 122 papers and 3.3k citations.

PubIndex Score98Top 2% · mid-careerHow it's scored

🌱#8 Emerging Leader in Melanoma and MAPK Pathways

122Publications

3.3kTotal Citations

#8in Melanoma and MAPK Pathways

First publication: 2002First senior author: 2016

Melanoma and MAPK Pathways Lung Cancer Treatments and Mutations PARP inhibition in cancer therapy Protein Kinase Regulation and GTPase Signaling Computational Drug Discovery Methods

Top publicationsby citations

The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling

Arvin C. Dar, Kevan M. Shokat|Annual Review of Biochemistry|2011

Cited by 391

Higher-Order Substrate Recognition of eIF2α by the RNA-Dependent Protein Kinase PKR

Arvin C. Dar, Frank Sicheri, Thomas Dever|Cell|2005

Cited by 387

Mechanistic Link between PKR Dimerization, Autophosphorylation, and eIF2α Substrate Recognition

Madhusudan Dey, Thomas Dever, Chune Cao et al.|Cell|2005

Cited by 367

Chemical genetic discovery of targets and anti-targets for cancer polypharmacology

Arvin C. Dar, Ross Cagan, Tirtha K. Das et al.|Nature|2012

Cited by 348

Formin Leaky Cap Allows Elongation in the Presence of Tight Capping Proteins

Sally H. Zigmond, M. Pring, Marie Evangelista et al.|Current Biology|2003

Cited by 265